On May 9, 2019, the Boston-based biotech company announced that it has agreed to pay $75 million to acquire a clinical trial of ZYNLONTA, a cancer treatment that targets elderly patients.  The deal is subject to approval by the U.S. Food and Drug Administration (FDA).  According to the SEC's complaint, ZYNLONTA was developed with the assistance of the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Justice (DHS).  ZYNLONTA is being developed with the assistance of the Department of Health and Human Services (DHS) and the Department of Justice (DHS).  The clinical trial that ZYNLONTA is developing will be conducted in academic and community centers.  ZYNLONTA has been approved by the FDA and the Department of Health and Human Services as a clinical trial.  ZYNLONTA's clinical trial is being conducted in the third line, third line plus setting.  The clinical trial is being conducted in the academic and community centers.  The clinical trial is being conducted in partnership with the Department of Health and Human Services.  ZYNLONTA is being developed in the academic and community centers.  The company's plans for ZYNLONTA are being reviewed by staff and internal analysts.  The SEC's complaint, filed in federal court in Boston, charges ZYNLONTA with violating the antifraud provisions of Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder.  The complaint also charges ZYNLONTA with violating Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and charges ZYNLONTA with violating Section 13(b) of the Exchange Act.  The complaint charges ZYNLONTA with violating Sections 206(1) and 206(2) of the Investment Advisers Act of 1940 and Rule 10b-5 thereunder, Sections 206(2) and 206(3) of the Investment Advisers Act of 1940, and Sections 206(4) and 206(8) of the Investment Advisers Act of 1940.  The complaint charges ZYNLONA with violating Section 17(a) of the Investment Advisers Act and Rule 206(4)-8 thereunder, Sections 206(1) and 206(4) of the Investment Advisers Act and Sections 206(2) and 206(4) of the Advisers Act.  The complaint charges ZYNL